KAPA vs KLRS

Kairos Pharma, Ltd. vs Kalaris Therapeutics, Inc. — Valuation Comparison 2026

KAPA

Biotechnology
Kairos Pharma, Ltd.
Quality
4.6
out of 10
Value Trap
12
SAFE
Price
$0.53
Last close
Models
7/13
Active
VS

KLRS

Biotechnology
Kalaris Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$5.18
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KAPA Fair ValueKAPA Upside KLRS Fair ValueKLRS Upside
Bayesian DCF Intrinsic $0.20 -62.4% $0.45 -91.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.23 -57.0% $1.17 -77.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KAPA vs KLRS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KAPA vs KLRS — Which Stock Is More Undervalued?

KAPA scores higher with a 4.6/10 quality rating vs KLRS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kairos Pharma, Ltd. (KAPA) and Kalaris Therapeutics, Inc. (KLRS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KAPA currently trades at $0.53 with a QOC of 4.6/10, while KLRS trades at $5.18 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).